Business Outlook: Leschly on to a winner in going for an encore

Bigger and more ambitious still grow the consolidating mergers of industry and finance. After months of fevered stock market speculation, Jan Leschly, chief executive of SmithKline Beecham, finally admitted publicly for the first time yesterday to plans for the big daddy of them all - a prospective merger with American Home Products to form a pharmaceuticals and health care products goliath with a combined market capitalisation of pounds 77bn. Just to put this in perspective, that's getting on for double the annual GDP of Ireland.

This is the world's most ambitious merger to date and it would be silly to try and belittle it in any way. All the same, by the end of the year we are going to have seen a lot more of these things, both domestic and like this one cross border in nature. It is all too likely that soon it will be eclipsed by something even bigger. The backdrop to this growing wave of mergers, not just in pharmaceuticals but across industries, sectors and frontiers, is well rehearsed. Globalisation, rapid technological change and a relentless pressure on managements for enhanced returns, is forcing the pace as never before.

Even so, it is somehow appropriate that it should be Mr Leschly who is out of the hatch first this year. He was not the architect of the original merger between Beecham and SmithKline, but he is credited with being the one who made it work, adding hugely to shareholder value in the process. Now this tough talking Dane is intent on performing an encore. He knows how to do these things and he knows how much value they can create.

Pharmaceuticals is in many respects already a truly global industry, in the sense that any company which can offer a medical advance will find its product used all over the world. Despite this and some already wopping pharmaceutical mergers, such as that between Glaxo and Wellcome three years ago, it is still a surprisingly fragmented industry, with no single company accounting for much more than 5 per cent of the world prescribed drugs market.

Actually what SmithKline is attempting here is not so much a quantum leap in size for pharmaceutical companies as a catching up with the market leaders. Even if Mr Leschly pulls this off, he still won't be quite as big as Merck. Nor will he be significantly larger in terms of sales and market capitalisation than Novartis, Pfizer and Glaxo Wellcome. But what he does do is achieve their economies of scale, and, just as important in this industry, their level of spend on research and development.

It is still sometimes the case that the boffin in his end of the garden shed will stumble across some new breakthrough in medical science. The biotechs are good examples of how this random approach to the blockbuster pharmaceutical product can still work. But on the whole this is not how it is done these days. New treatments for common ailments are achieved via very costly, systematic and targeted research into particular molecular structures, compounds and substances. Moreover, the costs of bringing a promising new compound from discovery to market are generally too big for anyone but the biggest players. So size matters.

The idea that there is no room any longer for the middle-ranked player, strongly locked into a particular domestic market, has become a bit of a business cliche. Companies have to be either the big global operator, with the distribution, spending and marketing clout to reach out to the mass markets of the world, or they they must position themselves as small niche players, sniping at the soft underbelly of the international monopolists. Perhaps unfortunately, it is nonetheless true. Mr Leschly is aiming to put SmithKline Beecham firmly in the first category.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksAn introduction to the ground rules of British democracy
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Mortgage Advisor - OTE £95,000

£40000 - £95000 per annum: Recruitment Genius: This is an exciting opportunity...

SThree: Trainee Recruitment Consultant

competitive: SThree: Are you passionate about sales?Do you have a keen interes...

Recruitment Genius: Loan Adviser - OTE £30,000

£17000 - £30000 per annum: Recruitment Genius: This is an exciting opportunity...

Recruitment Genius: Sales Assistant / Buyer

£15000 - £17000 per annum: Recruitment Genius: This company offers a range of ...

Day In a Page

Greece debt crisis: EU 'family' needs to forgive rather than punish an impoverished state

EU 'family' needs to forgive rather than punish an impoverished state

An outbreak of malaria in Greece four years ago helps us understand the crisis, says Robert Fisk
Gaza, a year on from Operation Protective Edge: The traumatised kibbutz on Israel's front line, still recovering from last summer's war with Hamas

Gaza, a year on from Operation Protective Edge

The traumatised kibbutz on Israel's front line, still recovering from last summer's war with Hamas
How to survive electrical storms: What are the chances of being hit by lightning?

Heavy weather

What are the chances of being hit by lightning?
World Bodypainting Festival 2015: Bizarre and brilliant photos celebrate 'the body as art'

World Bodypainting Festival 2015

Bizarre and brilliant photos celebrate 'the body as art'
alt-j: A private jet, a Mercury Prize and Latitude headliners

Don't call us nerds

Craig Mclean meets alt-j - the math-folk act who are flying high
How to find gold: The Californian badlands, digging out crevasses and sifting sludge

How to find gold

Steve Boggan finds himself in the Californian badlands, digging out crevasses and sifting sludge
Singing accents: From Herman's Hermits and David Bowie to Alesha Dixon

Not born in the USA

Lay off Alesha Dixon: songs sound better in US accents, even our national anthem
10 best balsamic vinegars

10 best balsamic vinegars

Drizzle it over salad, enjoy it with ciabatta, marinate vegetables, or use it to add depth to a sauce - this versatile staple is a cook's best friend
Wimbledon 2015: Brief glimpses of the old Venus but Williams sisters' epic wars belong to history

Brief glimpses of the old Venus but Williams sisters' epic wars belong to history

Serena dispatched her elder sister 6-4, 6-3 in eight minutes more than an hour
Greece says 'No': A night of huge celebrations in Athens as voters decisively back Tsipras and his anti-austerity stance in historic referendum

Greece referendum

Greeks say 'No' to austerity and plunge Europe into crisis
Ten years after the 7/7 terror attacks, is Britain an altered state?

7/7 bombings anniversary

Ten years after the terror attacks, is Britain an altered state?
Beautiful evening dresses are some of the loveliest Donatella has created

Versace haute couture review

Beautiful evening dresses are some of the loveliest Donatella has ever created
No hope and no jobs, so Gaza's young risk their lives, climb the fence and run for it

No hope and no jobs in Gaza

So the young risk their lives and run for it
Fashion apps: Retailers roll together shopping and social networking for mobile customers

Fashion apps

Retailers roll together shopping and social networking for mobile customers
The Greek referendum exposes a gaping hole at the heart of the European Union – its distinct lack of any genuine popular legitimacy

Gaping hole at the heart of the European Union

Treatment of Greece has shown up a lack of genuine legitimacy